U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07827261) titled 'A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer' on Sept. 14.
Brief Summary: This Phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 for injection in combination with glecirasib in the treatment of patients with locally advanced or metastatic non-small cell lung cancer with KRAS G12C mutation confirmed by histopathology and/or cytology.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Non-small Cell Lung Cancer
Intervention:
DRUG: BL-B01D1
Administration by intravenous infusion for a cyc...